logo
Plus   Neg
Share
Email

RIT Capital Partners Slips To Loss In H1; Declares Dividend

Investment company RIT Capital Partners Plc. (RCP.L) reported Tuesday that its first-half loss before tax was 68.9 million pounds, compared to last year's profit of 245.8 million pounds.

Loss per share was 44.2 pence, compared to profit of 158.5 pence last year.

Income and gains was negative 46.8 million pounds, compared to positive 268.1 million euros last year. Investment income declined to 8.8 million pounds from 14.6 million pounds last year.

Further, the Board has declared a second interim dividend of 17.5 pence per share for October, resulting in total dividend in 2020 of 35 pence per share, an increase of almost 3 percent over 2019.

Looking ahead, the company said, "The pandemic continues to exhibit unpredictable patterns, we are in the midst of a severe economic downturn, geopolitical risks are at a newly elevated level, and entire sectors of the economy face potentially radical adjustments to how they operate as well as rapidly changing societal expectations.... it is highly likely that there will be further bouts of volatility, which may be extreme, but which will provide opportunities for the nimble and astute investor."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pizza Hut's large Original Pan Pizza is now available at locations across the U.S. for $10.99. The fast food chain, a subsidiary of Yum! Brands Inc., said that fans can now get a large Original Pan Pizza with up to three of their favorite toppings, without needing to stretch their wallets. The Original Pan Pizza is a buttery golden-brown color. The U.S. Food and Drug Administration approved the first drug to treat adults and children aged 12 years and older with hypereosinophilic syndrome for six months or longer without another identifiable non-blood related cause of the disease. GlaxoSmithKline's Nucala (mepolizumab) is the first FDA-approved drug in nearly 14 years to treat this group of rare and debilitating blood diseases. Uber has won a legal battle to continue to operate in London, one of its largest markets. The ride-hailing company has been granted an 18-month license to operate in London after overturning the ban on an appeal for the second time. The Westminister Magistrates Court found Uber London Ltd. a "fit and proper" company to run the services in London.
RELATED NEWS
Follow RTT